# Study of Testosterone vs Placebo in Testicular Cancer Survivors

> **NCT02991209** · PHASE2,PHASE3 · COMPLETED · sponsor: **Mikkel Bandak** · enrollment: 69 (actual)

## Conditions studied

- Metabolic Syndrome
- Testicular Cancer
- Leydig Cell Failure in Adult

## Interventions

- **DRUG:** Testosterone
- **DRUG:** Placebos

## Key facts

- **NCT ID:** NCT02991209
- **Lead sponsor:** Mikkel Bandak
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-11
- **Primary completion:** 2019-06
- **Final completion:** 2019-06
- **Target enrollment:** 69 (ACTUAL)
- **Last updated:** 2020-03-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02991209

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02991209, "Study of Testosterone vs Placebo in Testicular Cancer Survivors". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT02991209. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*